TTK Healthcare Ltd.

TTK Healthcare Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

TTK Healthcare Ltd. has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across multiple timeframes. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s technical indicators reveal nuanced trends that investors should carefully analyse amid broader market pressures.

TTK Healthcare Ltd. has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest decline in price, the stock’s technical parameters reveal a complex interplay of bullish and bearish signals, underscoring the challenges faced by this micro-cap diversified sector player in the current market environment.

TTK Healthcare Ltd., a micro-cap player in the diversified sector, has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish stance. Despite a modest day gain of 1.60%, the stock’s broader technical indicators and price momentum reveal a complex picture, with mixed signals from MACD, RSI, moving averages, and other key metrics.

TTK Healthcare Ltd., a micro-cap player in the diversified sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action and technical parameters suggest increasing downside risks, prompting a downgrade in its mojo grade from Hold to Sell as of 21 July 2025.

TTK Healthcare Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

TTK Healthcare Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

TTK Healthcare Ltd., the Chennai-based diversified healthcare company known for its iconic Woodwards Gripewater brand, reported a robust net profit recovery of ₹21.76 crores in Q4 FY26, marking a sharp turnaround from the subdued ₹10.53 crores posted in the previous quarter. The sequential jump of 106.65% quarter-on-quarter brought some relief to investors, though the year-on-year comparison reveals a more modest gain of 34.73% over Q4 FY25's ₹16.15 crores. However, this profit resurgence comes against a backdrop of persistently weak operating margins and heavy reliance on non-operating income, raising questions about the sustainability of the company's earnings quality.

TTK Healthcare Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

TTK Healthcare Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

TTK Healthcare Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

TTK Healthcare Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

TTK Healthcare Ltd. has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend as of April 2026. Despite a modest day gain of 1.54%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other key metrics, reflecting cautious investor sentiment amid broader market challenges.

TTK Healthcare Ltd., a micro-cap player in the diversified sector, has experienced a notable shift in its technical momentum, with multiple indicators signalling a bearish trend. The stock’s recent price action and technical parameters suggest increasing downside pressure, reflecting a deteriorating outlook amid broader market challenges.

TTK Healthcare Ltd., a micro-cap player in the diversified sector, has experienced a subtle shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a modest daily gain of 2.09%, the stock’s broader trend remains cautiously bearish, prompting a recent downgrade from Hold to Sell by MarketsMOJO on 21 July 2025.

TTK Healthcare Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

TTK Healthcare Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.